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Abstract
Tau hyperphosphorylation is the first step of neurofibrillary tangle (NFT) for-
mation. In the present study, samples of the entorhinal cortex (EC) and frontal 
cortex area 8 (FC) of cases with NFT pathology classified as stages I– II, III– IV, 
and V– VI without comorbidities, and of middle- aged (MA) individuals with 
no NFT pathology, were analyzed by conventional label- free and SWATH- MS 
(sequential window acquisition of all theoretical fragment ion spectra mass 
spectrometry) to assess the (phospho)proteomes. The total number of identified 
dysregulated phosphoproteins was 214 in the EC, 65 of which were dysregulated 
at the first stages (I– II) of NFT pathology; 167 phosphoproteins were dysregu-
lated in the FC, 81 of them at stages I– II of NFT pathology. A large percentage 
of dysregulated phosphoproteins were identified in the two regions and at dif-
ferent stages of NFT progression. The main group of dysregulated phosphopro-
teins was made up of components of the membranes, cytoskeleton, synapses, 
proteins linked to membrane transport and ion channels, and kinases. The pre-
sent results show abnormal phosphorylation of proteins at the first stages of 
NFT pathology in the elderly (in individuals clinically considered representa-
tive of normal aging) and sporadic Alzheimer's disease (sAD). Dysregulated 
protein phosphorylation in the FC precedes the formation of NFTs and SPs. 
The most active period of dysregulated phosphorylation is at stages III– IV 
when a subpopulation of individuals might be clinically categorized as suffer-
ing from mild cognitive impairment which is a preceding determinant stage 
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1 |  INTRODUCTION
Sporadic Alzheimer's disease (sAD) is a progressive 
disorder characterized by the presence of neurofibril-
lary tangles (NFTs) and senile plaques (SPs) distributed 
with a distinctive pattern throughout the brain in old 
age; however, the first NFTs, although few in number, 
may appear in young adulthood or even before (1). The 
main constituent of NFTs in sAD is a combination of 
all six 3R and 4R hyper- phosphorylated brain tau iso-
forms (2, 3). Tau pathology is now widely accepted as key 
in the pathogenesis of AD and other tauopathies (4– 7). 
The study of consecutive series of the human population 
recognizes several stages of NFT pathology involving 
selected nuclei of the telencephalon and the brainstem, 
and increasing with age (8- 10). Most individuals with 
NFT pathology restricted to the transentorhinal and 
entorhinal cortices and part of the hippocampus (first 
stages: stages I– II) are cognitively normal; cases at mid-
dle stages (stages III– IV), in which there is the involve-
ment of the hippocampus and limbic system, may not 
suffer any apparent cognitive defect or suffer only mild 
cognitive impairment (MCI), often categorized as pre-
clinical AD (11); cases at stages V– VI (advanced stages) 
in which almost all the telencephalon and basal ganglia 
are filled with NFTs suffer from dementia and they are 
categorized as sAD (12). About 85% of individuals aged 
65 have NFT pathology, at least restricted to stages I– III 
(1, 13–15); only about 5% of them have dementia. The 
majority of individuals at stages I– II and almost half of 
those at stage III do not have SPs or β- amyloid deposits 
(13, 15). Increased numbers of SPs are common accom-
panying stage III– IV onwards. All cases with clinically 
and neuropathologically diagnosed sAD have NFTs 
stages V– VI and SPs; dementia of Alzheimer's type ac-
counts for about 25%– 30% of the population at the age 
of 85  years. In contrast, dementia with only tangles is 
exceptional. Therefore, sAD is an age- related continuum 
with variable timing of progression and strong individ-
ual variability, probably due to several genetic and envi-
ronmental factors, and which starts as a slow, silent state 
for decades in the majority of individuals, but may prog-
ress to cognitive impairment in some elderly individuals, 
and then convert to dementia in relatively few of them 
(15- 18). Recently, primary age- related tauopathy (PART) 
has been proposed to categorize a subpopulation of in-
dividuals with normal cognition or with mild cognitive 
impairment showing NFT pathology at stages I– IV of 
Braak and no SPs (19). Yet PART can also be interpreted 
within the spectrum of AD in cases with a particular ge-
netic background characterized by a lower prevalence 
of APOE e4, PTK2B, BIN1, and CR1 genes, and higher 
prevalence of APOE e2 (20- 22).
The presence of a few NFTs and SPs in the medial 
temporal cortex, and NFTs in selected nuclei of the 
brainstem, is considered normal aging in clinical terms 
in any individual in his/her sixties having tolerable dif-
ficulties retrieving names and numbers, some degree of 
memory loss, and perhaps mild symptoms of depression.
The general hypothesis of the present study is that (a) 
widespread molecular alterations precede, participate 
in, and progress in parallel to the formation of NFTs 
and SPs in sAD and that tau phosphorylation is one, 
albeit a crucial one, of the many abnormally phosphor-
ylated proteins in brain aging and sAD; (b) abnormal 
protein phosphorylation is determining in the dysfunc-
tion of numerous molecular pathways in brain aging 
and sAD. Pioneering studies have identified a few ab-
normally phosphorylated proteins in the hippocampus 
and cerebral cortex in small numbers of cases with AD 
compared with controls (23- 27). Using more accurate 
methods, large numbers of dysregulated phosphopro-
teins have been identified in the frontal cortex in sAD 
cases compared with controls (28- 30). However, we lack 
information about the alterations occurring at the first 
stages of NFT pathology (stages I– II) compared with the 
changes occurring at middle and advanced stages of dis-
ease progression.
To verify our hypothesis, the following objectives 
were decided upon: (1) identify abnormally phosphory-
lated proteins in two regions, the entorhinal cortex (EC) 
and frontal cortex area 8 (FC), differentially affected 
in aging and sAD; (2) learn whether abnormal protein 
phosphorylation develops at the first stages of NFT 
pathology without SPs in the FC in which the appear-
ance of NFTs would be expected several years later; (3) 
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by grant PT17/0019/009 to JFI, of the PE 
I + D+I 2013- 2016 funded by ISCIII and 
FEDER. Part of this work was funded 
by a grant from the Spanish Ministry of 
Science Innovation and Universities (Ref. 
PID2019- 110356RB- I00) to JFI and ES, and 
the Department of Economic and Business 
Development from the Government of 
Navarra (Ref. 0011- 1411- 2020- 000028) to 
ES
in the progression to dementia. Altered phosphorylation of selected proteins, 
carried out by activation of several kinases, may alter membrane and cytoskel-
etal functions, among them synaptic transmission and membrane/cytoskeleton 
signaling. Besides their implications in sAD, the present observations suggest 
a molecular substrate for “benign” cognitive deterioration in “normal” brain 
aging.
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(phospho)proteomics, Alzheimer's disease, brain aging, cytoskeleton, kinases, membranes, 
protein phosphorylation, synapses, tau
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identify the principal groups of abnormally phosphory-
lated proteins in terms of cell localization and function 
in aging and sAD; (4) infer from the obtained data which 
neuronal functions may be altered at the first and middle 
NFT stages; and (5) point to putative alterations con-
necting altered protein phosphorylation and β- amyloid 
production.
Conventional label- free- and SWATH- MS (Sequential 
window acquisition of all theoretical fragment ion spec-
tra mass spectrometry) were used to assess the (phos-
pho)proteomes across NFT staging in the EC and FC 
of pure cases with NFT pathology classified as stages 
I– II, III– IV, and V– VI without co- morbidities and asso-
ciated pathologies, and middle- aged (MA) individuals 
with no NFT pathology. Validation of a subgroup of 
proteins was carried out using immunohistochemistry 
and double- labeling immunofluorescence and confocal 
microscopy.
2 |  M ATERI A L A N D M ETHODS
2.1 | Tissue samples
Post- mortem samples were obtained from the Institute of 
Neuropathology HUB- ICO- IDIBELL Biobank follow-
ing the guidelines of Spanish legislation on this matter 
and the approval of the local ethics committee (CEIC) 
of Bellvitge University Hospital. The post- mortem in-
terval between death and tissue processing was between 
3 h and 11 h 15 min. One hemisphere was immediately 
cut in coronal sections, 1- cm thick, and selected areas of 
the encephalon were rapidly dissected, frozen on metal 
plates over dry ice, placed in individual air- tight plastic 
bags, numbered with water- resistant ink, and stored at 
−80℃ until used for biochemical studies. The other hem-
isphere was fixed by immersion in 4% buffered formalin 
for 3 weeks for morphologic study. Transversal sections 
of the spinal cord were alternatively frozen at −80℃ or 
fixed by immersion in 4% buffered formalin. The neuro-
pathological study was carried out on paraffin sections 
of twenty- five selected regions of the cerebrum, cerebel-
lum, brain stem, and spinal cord which were stained with 
hematoxylin and eosin, Klüver- Barrera, and periodic 
acid Schiff, or processed for immunohistochemistry with 
anti- β- amyloid, phospho- tau (clone AT8), α- synuclein, 
αB- crystallin, TDP- 43, TDP- 43- P, ubiquitin, p62, glial 
fibrillary acidic protein, CD68, and IBA1 antibodies (31).
Pathological cases (n  =  15) were those having 
NFT Braak stages I– II (n  =  5; 3  male, 2 women, 
68.8  ±  10.9  years), III– IV (n  =  5; 4  male, 1 female, 
77.2 ± 5.7 years), and V– VI (n = 5; 81 ± 7.5 years). Cases 
with associated pathology including other tauopathies, 
α- synucleinopathy, TDP- 43 proteinopathy, other neuro-
degenerative diseases, vascular diseases, and neoplastic 
diseases affecting the nervous system were excluded. 
Patients with arterial hypertension, type II diabetes, 
morbid obesity, hyperlipidemia, hepatic failure, renal 
failure, respiratory insufficiency, metabolic syndromes, 
and prolonged agonal states such as those occurring in 
intensive care units were eliminated. Cases with infec-
tious, inflammatory, or autoimmune diseases, either 
systemic or limited to the nervous system, were not in-
cluded. Middle- aged (MA) control cases (n = 9; 5 men, 4 
women; 58.8 ± 12.3 years) had not suffered from neuro-
logic or psychiatric diseases and did not have abnormal-
ities in the neuropathological examination including the 
absence of NFTs.
Table 1 summarizes the characteristics of cases used 
in this series. NFT pathology was categorized according 
to the staging of Braak and Braak (8) modified for par-
affin sections (32), β- amyloid deposits according to Thal 
phases (33), and CERAD scores according to the National 
Institute on Aging- Alzheimer's  Association guidelines 
for the neuropathologic assessment of Alzheimer's dis-
ease (34, 35). Cases 12 and 14, which were categorized 
as phase A1 of Thal, had diffuse plaques in the frontal 
cortex but not in the entorhinal cortex.
Frozen samples of the frontal cortex (area 8) (FC) 
and entorhinal cortex (EC) were separately examined in 
parallel.
2.2 | (Phospho)proteomic analysis
EC and FC samples derived from MA and NFT Braak 
stages I– II, III– IV, and V– VI cases were homogenized in 
a lysis buffer containing 7  M urea, 2  M thiourea, and 
50  mM DTT supplemented with protease and phos-
phatase inhibitors. The homogenates were spun down 
at 100,000 × g for 1 h at 15℃. Protein quantitation was 
performed with the Bradford assay kit (Bio- Rad). The 
EC and FC (phospho)proteomes and the corresponding 
proteomes across NFT staging were independently ana-
lyzed with conventional label- free- (36) and SWATH- MS 
(Sequential window acquisition of all theoretical frag-
ment ion spectra mass spectrometry) (37), respectively. 
A 1.3- fold change cutoff and p- value lower than 0.05 
were used for differential proteins and phosphopeptides. 
Proteins and phosphopeptides with ratios below the 
low range (0.77) were considered to be down- regulated, 
whereas those above the high range (1.3) were considered 
to be upregulated.
2.2.1 | Label- free phosphoproteomics
Six hundred micro grams of protein were used to obtain 
the phosphorylated fractions from EC and FC across 
NFT stages. For protein digestion, the reduction was 
performed with the addition of DTT to a final con-
centration of 10 mM and incubation at RT for 30 min. 
Subsequent alkylation with 30 mM (final concentration) 
iodoacetamide was performed for 30 min in the dark at 
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room temperature. An additional reduction step was car-
ried out with 30 mM DTT (final concentration), allowing 
the reaction to stand at room temperature for 30  min. 
The mixture was diluted to 0.6  M urea using MilliQ- 
water, and after the addition of trypsin (Promega) (en-
zyme: protein, 1:50 w/w), the sample was incubated at 
37℃ for 16 h. Digestion was quenched by acidification 
(pH < 6) with acetic acid. After protein enzymatic cleav-
age, peptide cleaning was performed using Pierce™ 
Peptide Desalting Spin Columns (ThermoFisher). To 
obtain the phosphorylated peptide fractions, the High- 
Select™ TiO2 Phosphopeptide Enrichment Kit (Thermo 
Scientific) was used according to the manufacturer's 
instructions. Phosphopeptide mixtures were separated 
by reversed- phase chromatography using an Eksigent 
NanoLC ultra 2D pump fitted with an Acclaim™ 
PepMap™ 100 C18 column (0.075  ×  250  mm, particle 
size 3 µm; ThermoFisher). Samples were first loaded for 
concentration into an Acclaim™ PepMap™ 100 C18 trap 
column (0.1 × 20 mm, particle size 5 µm; ThermoFisher). 
Mobile phases were 100% water 0.1% formic acid (FA) 
(buffer A), and 100% acetonitrile 0.1% FA (buffer B). The 
column gradient was developed in a gradient from 2% 
B to 40% B in 120 min. The column was equilibrated in 
95% B for 10 min and 2% B for 10 min. During the entire 
process, the precolumn was in line with the column, and 
flow was maintained all along the gradient at 300 nl/min. 
The eluting peptides were analyzed using a 5600 Triple- 
TOF mass- spectrometer (Sciex). Information data ac-
quisition was made with a survey scan performed in a 
mass range from 350 up to 1250  m/z in a scan time of 
25  ms. The top 15 peaks were selected for fragmenta-
tion. The minimum accumulation time for MS/MS was 
set at 200 ms giving a total cycle time of 3.3 s. The pro-
duced ions were scanned in a mass range from 100 up 
to 1500 m/z and excluded for further fragmentation for 
15  s. The raw MS/MS spectra searches were processed 
using the MaxQuant software (v 1.6.7.0) and searched 
against the Uniprot proteome reference for Homo sapiens 
(Proteome ID: UP000005640_9606, February 2019). The 
parameters used were as follows: initial maximum pre-
cursor (15 ppm) fragment mass deviations (20 ppm); fixed 
TA B L E  1  Summary of cases used in this study









1 M 62 3 h 20 min A0 B0 C0 EC C
2 F 54 8 h A0 B0 C0 EC C
3 M 33 8 h 15 min A0 B0 C0 EC C
4 F 51 4 A0 B0 C0 EC C
5 M 54 8 h 45 min A0 B0 C0 EC, FC C
6 F 65 4 h A0 B0 C0 FC C
7 M 62 3 h A0 B0 C0 FC C
8 M 70 13 h 40 min A0 B0 C0 FC C
9 F 79 7 h A0 B0 C0 FC C
10 M 63 3 h 50 min A0 I– II (B1) C0 EC, FC N
11 M 64 8 h 35 min A0 I– II (B1) C0 EC, FC N
12 M 86 5 h 35 min A1 I– II (B1) C0 EC, FC N
13 F 55 9 h 30 min A0 I– II (B1) C0 EC, FC N
14 F 76 5 h 45 min A1 I– II (B1) C0 EC, FC N
15 M 85 4 h 45 min 2 (A1) III– IV (B2) C2 EC, FC MCI
16 M 75 6 h 10 min A1 III– IV (B2) C1 EC, FC N
17 M 77 11 h 15 min 2 (A1) III– IV (B2) C2 EC, FC N
18 M 81 7 h 30 min 3 (A2) III– IV (B2) C2 EC, FC MCI
19 F 68 4 h 45 min 2 (A1) III– IV (B2) C2 EC, FC N
20 M 92 7 h 45 min 3 (A2) V– VI (B3) C3 EC, FC A dementia
21 M 85 3 h 45 min 4 (A3) V– VI (B3) C3 EC, FC A dementia
22 F 84 7 h 45 min 4 (A3) V– VI (B3) C3 EC, FC A dementia
23 M 82 5 h 4 (A3) V– VI (B3) C3 EC, FC A dementia
24 W 72 9 h 30 min 4 (A3) V– VI (B3) C3 EC, FC A dementia
Note: Amyloid/Thal phases (1: deposits exclusive in neocortex, 2: plus allocortex, 3: plus diencephalic nuclei, striatum, and nuclei of the basal forebrain, 4: plus 
brainstem; modified NIA- AA: A0, A1, A2, A3, A4); NFT/Braak stages: Braak stages of neurofibrillary tangle pathology (modified B0, B1, B2, B3); CERAD/
neuritic plaque scores (C0: none, C1: sparse, C2: moderate, C3: frequent).
Abbreviations: A dementia, Alzheimer's dementia; C, control; EC, entorhinal cortex; F, female; FC, frontal cortex area 8; M, male; MCI, mild cognitive 
impairment; N, cognitively normal; PMD, post- mortem delay.
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modification [Carbamidomethyl (C)]; variable modi-
fication [Oxidation (M)]; Acetyl [Protein N- terminal; 
Deamidation (N); Gln  >  puroGlu; Phospho (STY)]; 
enzyme (trypsin) with a maximum of 1  missed cleav-
age; minimum peptide length (7 amino acids); and false 
discovery rate (FDR) for PSM and protein identification 
(1%). Frequently observed laboratory contaminants were 
removed. The Perseus software (version 1.5.6.0) was used 
for statistical analysis and data visualization.
2.2.2 | SWATH- MS
For protein expression analysis, 2 independent pools 
of multiple human brain structures were used as input 
for the generation of the SWATH- MS essay library. To 
increase proteome coverage, in- solution and in- gel di-
gestion workflows were applied. In the first case, pro-
tein material from each pooled sample was precipitated 
using methanol/chloroform extraction. The pellet was 
dissolved in 6  M urea, 100  mM Tris, pH 7.8. Protein 
digestion was performed as described above. The di-
gestion mixture was dried in a SpeedVac, reconstituted 
with 110 µL 5 mM ammonium formate pH 10, and in-
jected into an ÄKTA pure 25  system (GE Healthcare 
Life Sciences) with a high pH stable X- Terra RP18 col-
umn (C18; 1  mm  ×  150  mm; 5  μm) (Waters). Peptides 
were eluted with a mobile phase B (5  mM ammonium 
formate in 90% ACN at pH 10) of 30– 70% linear gra-
dient over 45 min (A, 5 mM ammonium formate in the 
water at pH 10; B, 5  mM ammonium formate in 90% 
ACN at pH 10). The UV signal was monitored at 215 nm. 
Fractions were collected and evaporated in a vacuum. 
Neighboring fractions with low signal intensity were 
subsequently pooled to generate fractions with simi-
lar peptide content. For the second digestion protocol, 
protein extracts (20 ug) were diluted in Laemmli sample 
buffer and loaded into a 1.5  mm thick polyacrylamide 
gel with a 4% stacking gel cast over a 12.5% resolving gel. 
The total gel was stained with Coomassie Brilliant Blue, 
and 12  equal slides from each pooled sample were ex-
cised from the gel and transferred into 1.5 ml Eppendorf 
LoBind tubes. Protein enzymatic cleavage was carried 
out with trypsin (Promega; 1:20, w/w) at 37℃ for 16  h 
as previously described (38). Purification and concen-
tration of peptides were performed using C18 Zip Tip 
Solid Phase Extraction (Millipore). The peptides, recov-
ered from in- gel and in- solution digestion processing, 
were reconstituted into a final concentration of 0.5 µg/
µl of 2% ACN, 0.5% FA, 97.5% MilliQ- water before mass 
spectrometric analysis. MS/MS datasets for spectral li-
brary generation were acquired on a TripleTOF 5600+ 
mass spectrometer (Sciex) interfaced to the Eksigent 
nanoLC ultra 2D pump system (Sciex) as previously de-
scribed. MS/MS data acquisition was performed using 
AnalystTF 1.7 (Sciex), and spectra files were processed 
through ProteinPilot v5.0  search engine (Sciex) using 
ParagonTM Algorithm (v.4.0.0.0) (39) for database search. 
To avoid using the same spectral evidence in more than 
one protein, the identified proteins were grouped based 
on MS/MS spectra with the Progroup™ Algorithm, re-
gardless of the peptide sequence assigned. False discov-
ery rate (FDR) was determined using a non- linear fitting 
method (40) and displayed results were those reporting 
a 1% Global FDR or better. Then, individual protein 
extracts from all sample sets (n = 40) were subjected to 
in- solution digestion, peptide purification, and recon-
stitution before mass spectrometric analysis as previ-
ously mentioned. For SWATH- MS- based experiments, 
the TripleTOF 5600+ instrument was configured as 
described by Gillet et al. (41). Using an isolation width 
of 16 Da (15 Da of optimal ion transmission efficiency 
and 1 Da for the window overlap), a set of 37 overlap-
ping windows was constructed covering the mass range 
450– 1000 Da. In this way, 1 μl of each sample was loaded 
onto an Acclaim™ PepMap™ 100 C18 trap column 
(0.1  ×  20  mm, particle size 5  µm; ThermoFisher) and 
desalted with 100% water 0.1% formic acid at 2 μl/min 
for 10 min. The peptides were loaded onto an Acclaim™ 
PepMap™ 100 C18 column (0.075  ×  250  mm, particle 
size 3 µm; ThermoFisher) equilibrated in 2% acetonitrile 
0.1% FA. Peptide elution was carried out with a linear 
gradient of 2 to 40% B in 120  min (mobile phases A: 
100% water 0.1% formic acid (FA) and B: 100% acetoni-
trile 0.1% FA) at a flow rate of 300 nl/min. Eluted pep-
tides were infused in the mass- spectrometer. The Triple 
TOF was operated in SWATH mode, in which a 0.050 s 
TOF MS scan from 350 to 1250 m/z was performed, fol-
lowed by 0.080 s product ion scans from 230 to 1800 m/z 
on the 37 defined windows (3.05  s/cycle). The collision 
energy was set to optimum energy for a 2+ ion at the 
center of each SWATH block with a 15 eV collision en-
ergy spread. The resulting ProteinPilot group file from 
library generation was loaded into PeakView® (v2.1, 
Sciex), and peaks from SWATH runs were extracted 
with a peptide confidence threshold of 99% (Unused 
Score ≥1.3) and FDR lower than 1%. For this, the MS/
MS spectra of the assigned peptides were extracted with 
ProteinPilot, and only the proteins that fulfilled the fol-
lowing criteria were validated: (1) peptide mass tolerance 
lower than 10 ppm, (2) 99% confidence level in peptide 
identification, and (3) complete b/y ions series found in 
the MS/MS spectrum. Only proteins quantified with 
at least two unique peptides were considered. The cel-
lular localization and main functions of the differential 
proteins were retrieved from www.genec ards.org; www.
unipr ot.org; www.ebi.ac.uk (InterPro); www.OMIM.org; 
www.ncbi.nlm.nih.org. All MS raw data and search re-
sult files have been deposited at the ProteomeXchange 
Consortium (http://prote omece ntral.prote omexc hange.
org) via the PRIDE partner repository with the data-
set identifiers PXD021645 (Reviewer account details: 
Username:  reviewer_pxd021645@ebi.ac.uk; Password: 
ANBskoaI) and PXD021653 (Reviewer account details: 
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Username:  reviewer_pxd021653@ebi.ac.uk; Password: 
kMAyoOkq).
2.2.3 | Bioinformatics
The identification of significantly dysregulated regula-
tory/metabolic pathways in EC and FC proteomic data-
sets was made using Metascape (42). Network analysis 
was performed by submitting the corresponding protein 
IDs to the STRING (Search Tool for the Retrieval of 
Interacting Genes) software (http://strin gdb.org/) (43). 
Proteins are represented with nodes and all the edges 
were supported by at least one reference from the lit-
erature or canonical information stored in the STRING 
database. To minimize false positives as well as false 
negatives, only interactions tagged as “medium confi-
dence” (>0.4) in STRING database were considered.
2.3 | Immunohistochemistry and 
double- labeling immunofluorescence and 
confocal microscopy
Formalin- fixed, paraffin- embedded 4  μm- thick tis-
sue sections of the EC and FC were obtained with a 
sliding microtome. The sections were processed for 
immunohistochemistry. The sections were boiled in 
citrate buffer (20 min) to retrieve protein antigenicity. 
Endogenous peroxidases were blocked by incubation 
in 10% methanol– 1% H2O2  solution (15  min) followed 
by 3% normal horse serum solution. Then the sections 
were incubated at 4℃ overnight with one of the pri-
mary antibodies listed in Table 2. Following incubation 
with the primary antibody, the sections were incubated 
with EnVision  +  system peroxidase (Dako, Agilent 
Technologies, Santa Clara, CA, USA) for 30  min at 
room temperature. The peroxidase reaction was visual-
ized with diaminobenzidine and H2O2. Control of the 
immunostaining included omission of the primary anti-
body; no signal was obtained following incubation with 
only the secondary antibody.
For double- labeling immunofluorescence, the tissue 
sections were stained with a saturated solution of Sudan 
black B (Merck, Glostrup, DE) for 15 min to block the 
autofluorescence of lipofuscin granules present in cell 
bodies, and then rinsed in 70% ethanol and washed 
in distilled water. The sections were incubated at 4℃ 
overnight with combinations of primary antibodies 
AT8 and anti- p38  kinase P Thr180/Tyr182 or PKAα/β 
Thr197. After washing, the sections were incubated 
with Alexa488 and Alexa546 (1:400, Molecular Probes, 
Eugene, OR, USA) fluorescence secondary antibodies 
against the corresponding host species. Nuclei were 
stained with DRAQ5TM (dilution 1:2000, BioStatus, 
Loughborough, UK). After washing, the sections were 
mounted in Immuno- Fluore mounting medium (ICN 
Biomedicals, Irvine, CA, USA), sealed, and dried over-
night. Sections were examined with a Leica TCS- SL 
confocal microscope.
3 |  RESU LTS
To quantify region- dependent fluctuations on a 
proteome- wide scale, we performed an integrative analy-
sis of the proteome and phosphoproteome across NFT 
stages in the EC and FC.
TA B L E  2  Antibodies used
Antibody Supplier Reference Species Dilution hi
AT8 Innogenetics clone AT- 8 ms 1:50
Catenin β- P Ser45/Thr41 Cell Signaling 9565 rb 1:50
MAP2- P Thr1620/1623 Cell Signaling 4544 rb 1:1000
Adducin 1- (ADD1) P Ser726 Abcam ab53093 rb 1:100
ADD1/ADD2- P Ser726/Ser713 Thermo- Fisher Invitrogen PA5- 36614 rb 1:100
p38- P Thr180/Tyr182 Cell Signaling 9211 rb 1:100
SAPK/JNK- P Thr183/Thr185 Cell Signaling 9251 rb 1:50
PAK1- P Ser199/Ser204 Merck- Sigma- Aldrich 09- 258 rb 1:100
NFL- P Ser473 (clone 4F8) Merck- Sigma- Aldrich MABN2431 ms 1:100
NFH Abcam Ab8135 rb 1:1000
NFH (200 kDa) RT97 Merck- Sigma- Aldrich Mab5262 ms 1:50
NFM (160 kDa) BF10 Boehringer 1178687 ms 1:50
PAK1- P Ser199/Ser204 Merck- Sigma- Aldrich 09- 258 rb 1:100
Abbreviations: MAP2, microtubule- associated protein 2; NFH, NF high molecular weight; NFL, neurofilament low molecular weight; NFM, NF medium 
molecular weight; p38, p38 kinase; PKAα/β, protein kinase A α/β; SAPK/JNK, Stress- activated protein kinase (SAPK)/Jun amino- terminal kinase (JNK).
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3.1 | Proteome and phosphoproteome 
dynamics in the EC
Heatmaps of proteomes and phosphoproteomes showed 
marked differences in the EC between MA and the dif-
ferent stages of NFT pathology. The total number of 
different identified dysregulated proteins was 230 (57 at 
stage I– II, 89 at stage III– IV, and 136 at stage V– VI). 
The total number of different identified dysregulated 
phosphoproteins was 214, corresponding to 65 at stages 
I– II, 135 at stages III– IV, and 118 at stages V– VI (total 
number of phosphosites 83, 225, and 195, respectively) 
(Figure 1A). Some of them were common to different 
stages. Direction of dysregulation (hyper- or hypophos-
phorylation compared to MA) was variable depending 
on the stage, with no apparent predetermined patterns. 
Some phosphoproteins showed more than one phospho-
rylation site; the direction of phosphorylation (hyper- or 
hyporegulation) was independent of the phosphoryla-
tion site (Table S1).
Comparison between total dysregulated proteins 
and dysregulated phosphoproteins showed 42 dysreg-
ulated phosphoproteins not accompanied by concom-
itant altered expression of their total corresponding 
protein levels, 23 not quantified, and 0 overlapping at 
stages I– II (total phosphoproteins 65); 93 dysregulated 
phosphoproteins not accompanied by concomitant al-
tered expression of their corresponding total protein 
levels, 42 not quantified, and 3 phosphoproteins with 
altered steady- state protein levels at stages III– IV (total 
phosphoproteins 135); and 83 dysregulated phosphopro-
teins not accompanied by concomitant altered expres-
sion of their total corresponding protein level, 35 not 
quantified, and 7 phosphoproteins with altered levels of 
the total protein at stages V– VI (total phosphoproteins 
118) (Table S2).
Comparative analysis of different stages revealed 
22 phosphoproteins common to the three stages, 40 
phosphoproteins common to stages V– VI and III– IV, 10 
phosphoproteins common to stages V– VI and I– II, and 
10 phosphoproteins common to stages III– IV and I– II 
(Figure 1B). A comparative diagram of common and 
stage- specific dysregulated proteins is shown in the same 
figure where no overlap is seen between dysregulated pro-
teins and dysregulated phosphoproteins at the different 
NFT stages.
To characterize in detail the entorhinal proteostatic 
modulation across NFT stages, differential proteomic 
and phosphoproteomic datasets were merged, and 
then functionally analyzed across specific biological 
functions. The phosphoprotein overlap previously de-
scribed was also accompanied by a considerable over-
lap in the significantly enriched GO terms across NFT 
stages associated with cell morphogenesis involved in 
differentiation, synapse organization, vesicle- mediated 
transport, nervous system development, chemical 
synaptic transmission, neuronal systems, response to 
wounding, regulation of membrane potential, synap-
tic vesicle cycle, ECM- receptor interaction, regulated 
exocytosis, protein localization to membrane, regula-
tion of vesicle- mediated transport, regulation of system 
process, dendritic development, cellular response to ex-
ternal stimuli, microtubule cytoskeleton organization, 
and regulation of cell morphogenesis (Table S3). The 
number of disrupted pathways increased with disease 
progression when considering the sum of disrupted 
pathways across NFT staging, disrupted pathways com-
mon to stages III– IV and V– VI, and disrupted pathways 
at stages V– VI. Importantly, many disrupted pathways 
were common to the first (I– II), middle (III– IV), and 
advanced (V– VI) stages, thus indicating a continuity of 
altered putative function derived from aberrant proteo-
stasis starting at the first stages of the biological pro-
cess (Figure 2).
3.2 | Proteome and phosphoproteome 
dynamics in the FC
The total number of identified dysregulated proteins 
was 82 (23 at stage I– II, 31 at stage III– IV, and 37 at 
stage V– VI) compared with MA. The total number of 
identified dysregulated phosphoproteins was 167, cor-
responding to 81 at stages I– II, 92 at stages III– IV, and 
79 at stages V– VI (total number of phosphosites 100, 
129, and 101, respectively) (Figure 3A; Table S2). The 
direction of dysregulation (hyper- or hypophosphoryla-
tion compared to MA) was variable depending on the 
stage and region with no apparent predetermined pat-
terns (Table S4).
Comparison between total dysregulated proteins and 
dysregulated phosphoproteins showed 56 dysregulated 
phosphoproteins without concomitant variation in total 
protein levels at stages I– II, 61 at stages III– IV, and 55 at 
stages V– VI; not quantified were 25, 31, and 24 at stages 
I– II, III– IV, and V– VI, respectively (Table S2).
The comparative analysis between different stages re-
vealed 21 phosphoproteins common to the three stages, 
14 phosphoproteins common to stages V– VI and III– IV, 
14 (phospho)proteins common to stages V– VI and III– IV, 
14 (phospho)proteins common to stages V– VI and I– II, 
and 15 phosphoproteins common to stages III– IV and 
I– II (Figure 3B). No overlap was observed between dys-
regulated proteins and dysregulated phosphoproteins at 
the different NFT stages.
As observed in the EC, a functional overlap was also 
detected in the FC during NFT staging progression, 
revealing alterations in actin filament- based process, 
cellular morphogenesis, synapse organization, axon 
guidance, cell junction organization, maintenance of 
cell polarity, neurexins, and neuroligins, negative regu-
lation of cellular components organization, semaphorin 
interactions, chemical synaptic transmission, neuronal 
systems, muscle system process, positive regulation of 
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cellular components movements, apoptosis, dendrite 
development, transport along the microtubule, positive 
regulation of hydrolase activity, establishment of organ-
elle localization, and actomyosin structure organization 
(Table S5). The heatmap of common and stage- specific 
altered functions in the FC across NFT staging is shown 
in Figure 4. The figure also serves to highlight how sev-
eral functional pathways are altered at the first and mid-
dle stages of the process while many are altered at stages 
I– II, III– IV, and V– VI.
F I G U R E  1  (A) Heatmap representation showing both clustering and the degree of change for the differentially expressed (phospho)
proteins in NFT I– II (left), NFT III– IV (middle), and NFT V– VI (right) at the EC. (B) Common and unique differential EC (phospho)proteins 
across NFT staging. Venn diagrams show the overlap between differential EC proteins (left) and (phospho)proteins (right) across NFT staging. 
Gene names are indicated for the corresponding overlapping areas
   | 9 of 38PROTEIN PHOSPHORYLATION IN BRAIN AGING AND AD
F I G U R E  2  Enriched ontology clusters in the EC differential (phospho)proteomes during NFT progression. After identification of all 
statistically enriched terms, cumulative hypergeometric p- values and enrichment factors were calculated and used for filtering. The remaining 
significant terms were then hierarchically clustered into a tree based on Kappa- statistical similarities among their gene memberships. Then, 
a 0.3 kappa score was applied as the threshold to cast the tree into term clusters. The term with the best p- value within each cluster was 
selected as its representative term and displayed in a dendrogram. The heat map cells are colored for their p- values; grey cells indicate a lack of 
enrichment
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F I G U R E  3  (A) Heatmap representation showing both clustering and the degree of change for the differentially expressed (phospho)
proteins in NFT stages I– II (left), NFT III– IV (middle), and NFT V– VI (right) in the FC. (B) Common and unique differential FC (phospho)
proteins across NFT staging. Venn diagrams show the overlap between differential FC proteins (left) and phosphoproteins (right) during AD 
progression. Gene names are indicated for the corresponding overlapping areas
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F I G U R E  4  Enriched ontology clusters in FC differential (phospho)proteomes during AD progression. After identification of all 
statistically enriched terms, cumulative hypergeometric p- values and enrichment factors were calculated and used for filtering. The remaining 
significant terms were then hierarchically clustered into a tree based on Kappa- statistical similarities among their gene memberships. Then, a 
0.3 kappa score was applied as the threshold to cast the tree into term clusters. The term with the best p- value within each cluster was selected 
as its representative term and displayed in a dendrogram. The heat map cells are colored for their p- values; grey cells indicate the lack of 
enrichment
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3.3 | Individualized analysis of differentially 
phosphorylated proteins expressed in the 
EC and FC
To better characterize the relevance of differentially 
phosphorylated proteins and their implication in the 
pathobiology of sAD, phosphoproteins were manually 
categorized into several groups one by one according to 
their localization and function. Cytoskeletal and mem-
brane proteins, proteins of the synapses and dense core 
vesicles, myelin proteins, and proteins linked to mem-
brane transport and ion channels accounted for 144 dif-
ferentially phosphorylated proteins. Their symbols, full 
names, main functions, and presence in the EC and FC 
at different stages of NFT pathology are summarized in 
Table 3.
The largest group of dysregulated phosphoproteins 
was made up of cytoskeletal and membrane proteins 
(n  =  91) which included proteins of microfilaments, 
actin- binding proteins, intermediate filaments of neu-
rons and glial cells, proteins associated with micro-
tubules, integral membrane proteins, and peripheral 
membrane proteins. The EC and FC shared thirty- one 
proteins abnormally phosphorylated. Thirty- five pro-
teins were identified as differentially phosphorylated in 
at least two stages in the EC and 28 proteins in the FC 
in AD when compared with MA. Twenty- three dysregu-
lated phosphoproteins were identified in only one region 
or one stage of the disease. A second group was made 
up of phosphoproteins of the synapses and dense core 
vesicles (n = 21). This classification was instrumental as 
some membrane proteins also participated in the struc-
ture of the synapses, and several synaptic proteins were 
considered plasma membrane proteins. Six proteins were 
identified in both the EC and FC. Four proteins were 
differentially phosphorylated in two stages of AD in the 
EC, and five in the FC. Twelve proteins were identified 
in only one region or one stage of the disease. The third 
group included a few myelin- associated phosphopro-
teins (myelin basic protein, myelin proteolipid protein, 
and 2′,3′- cyclic nucleotide 3′ phosphodiesterase). The 
fourth group was represented by phosphoproteins linked 
to membrane transport and ion channels (n = 28). Eight 
dysregulated phosphorylated proteins were common to 
the EC and FC: Seven phosphoproteins were altered in 
two stages in AD in the EC, and twelve in the FC. Ten 
dysregulated phosphoproteins were identified in only 
one region or one stage of the disease.
Other dysregulated phosphoproteins were catego-
rized as kinases, proteins linked to DNA or protein 
deacetylation, proteins linked to gene transcription 
and protein synthesis, heat- shock proteins, members of 
the ubiquitin- proteasome system (UPS), and proteins 
involved in energy metabolism. The list included 77 
phosphoproteins. Their symbols, full names, main func-
tions, and occurrence in the EC and FC at different stages 
of NFT are summarized in Table 4. Twenty- one kinases 
with dysregulated phosphorylation were identified. Five 
(phospho)proteins linked to DNA were dysregulated in 
the EC, all of them at stages III– IV and/or V– VI. Two 
were dysregulated in the FC. Another major group was 
composed of 31 dysregulated phosphoproteins linked 
to gene transcription and protein synthesis. Eighteen 
phosphoproteins were detected in the EC, eighteen in the 
FC, and thirteen in at least two stages in the FC or EC. 
Dysregulated phosphorylation of heat- shock proteins 
was found in the EC at stages III– IV and V– VI. Seven 
phosphoproteins involved in the UPS were abnormally 
regulated, five of them only in the EC, and only one in 
two stages. Only two phosphoproteins linked to the UPS 
were abnormally regulated in the FC. Finally, the distri-
bution of abnormally regulated phosphoproteins linked 
to energy metabolism was largely region- dependent. Of 
the total 14 dysregulated phosphoproteins, only three 
were common to the EC and FC. Other dysregulated 
phosphoproteins were heterogeneous and identified in 
only one stage and in one region (Tables S1 and S4).
3.4 | Dysregulated phosphoproteins at the 
first stages of NFT pathology
Several phosphoproteins linked to the structure and 
function of cell membranes, cytoskeleton, and synapses 
were dysregulated at the first stages of NFT pathology 
in the EC and FC. Thirty- six phosphoproteins were dys-
regulated in the EC at stage I– II in comparison with MA 
individuals. Forty- seven phosphoproteins were abnor-
mally regulated in the FC at stage I– II (Table 3).
Dysregulated phosphorylation of proteins categorized 
as kinases, proteins linked to DNA or protein deacetyl-
ation, proteins linked to gene transcription and protein 
synthesis, and proteins involved in energy metabolism 
also occurred in the EC and FC at the first stages of NFT 
pathology. Nineteen phosphoproteins were dysregulated 
in the EC at stages I– II compared with MA. Twenty- five 
dysregulated phosphoproteins were identified in the FC 
at stages I– II (Table 4).
3.5 | Interactions of dysregulated 
phosphoproteins linked to the structure and 
function of cell membranes, synapses, and 
cytoskeleton
The interactions of dysregulated phosphoproteins in 
the EC and FC at different stages of NFT pathology are 
summarized in Figure 5. Protein tau interacts with sev-
eral proteins but many others have no direct interactions 
with tau, thus suggesting that the phosphorylation of a 
particular protein does not necessarily depend on the 
phosphorylation state of tau. As detailed above, dysreg-
ulated protein phosphorylation started at the first stages 
of NFT pathology. The greater number of different 
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TA B L E  3  Dysregulated cytoskeletal, synaptic, and membrane phosphoproteins in the entorhinal cortex (EC) and frontal cortex area 8 











ACTB Actin cytoplasmic 1; 
actin β
Main component of 
microfilaments
NEFM Neurofilament medium 
polipeptide
Intermediate neurofilaments
NEFH Neurofilament heavy 
polipeptide
INA α- internexin Intermediate neurofilament 
enriched in frontal cortex
TUBA1B Tubulin α- 1B chain Components of microtubules
TUBGCP3 γ- tubulin complex 
component 3
TPPP Tubulin polimerization 
promoting protein
MAP1A Microtubule- associated 
protein 1A
MAP1B Microtubule- associated 
protein 1B
MAP2 Microtubule associated 
protein 2
MAPT Microtubule associated 
protein tau
MAP1S Microtubule associated 
1S
DYNC1LI1 Cytoplasmic dynein 
1 light intermediate 
chain 1
Dyneins transport cargos 
along microtubules and are 
responsible of retrograde 
axonal transportDYNC1LI2 Cytoplasmic dynein 
1 light intermediate 
chain 2
DYNC 1/1 Cytoplasmic dynein 
intermediate chain
KIF21A Kinesin- like protein 
KIF21A
Kinesins facilitate anterograde 
axonal transport
NFASC Neurofascin IGcam organization axon 
initial segment
SEPTIN9 Septin9 Growth and stability of axons, 
dendrites and synapses
SEPTIC4 Septin4 GTPase activity; cytoskeleton 
dependent cytokinesis
PLEC Plectin Binding cytoskeleton
DPYSL2 Dydropyrimidinase- 
related protein
Member of the collapsing 
response mediator 
protein family; promotes 
microtubule assembly
CAP2 Adenylyl cyclase- 
associated protein
Interaction with actin












I– II FC III– IV
FC 
V– VI
IQSEC1 IQ motif and SEC7 
domain- containing 
protein 1
Endocytosis of plasma 
membrane proteins; 
E- cadherin recycling 
and actin cytoskeleton 
remodelling; enriched in 
the frontal cortex
GFAP Glial fibrillary acidic 
protein
Cytoskeleton of astrocytes
VIM Vimentin Major intermediate filament in 
mesenchymal cells
FEZ1 Fasciculation and 
elongation protein 
Z − 1
Axon elongation in C. elegans
MYH9 Myosin 9 Actin- binding protein
MYL12A Myosin regulatory like Myosin heavy chain binding
CTNNA1 Catenin alpha 1 Anchorage of actin filaments 
to the sarcolemma
CTNNA2 Catenin alpha 2 Binding cadherins and actin- 
containing filaments of the 
cytoskeleton
CTNND2 Catenin delta Connecting cadherins to actin 
filaments
ANK2 Ankyrin- 2 Link the integral membrane 
proteins to the spectrin- 
actin cytoskeleton
ANK3 Ankyrin- 3 Clustering of voltage- gated 
sodium channels at the 
axon hillock
ANKRD13D Ankyrin repeat domain- 
containing protein 
13D
Ubiquitin- binding protein; 
negative regulation of 
receptor internalization
VCL Vinculin Anchoring actin to membranes
PALM Paralemmin 1 Component of the cytoplasmic 
face of the plasma 
membranes
SPTBN1 Spectrin beta chain, non- 
erythrocytic 1
Binding the plasma membrane 
to the cytoskeleton
CAMSAP1 Calmodulin- regulated 
spectrin- associated 
protein 1
Stabilization of the 
microtubules
CDH10 Cadherin Cell adhesion molecle (CAM); 
calcium dependent 
transmembrane protein 
linked to cell junctions




TJP1 Tight junction protein 1 Membrane- associate guanylate 
kinase (MAGUK) 
homologues; link F- actin to 
trans- membrane proteins; 
TJP1 enriched in the post- 
synaptic membrane
TJP2 Tight junction protein 
ZO- 2
TA B L E  3  (Continued)
(Continues)







I– II FC III– IV
FC 
V– VI
MPP2 Membrane palmitolated 
protein 2
Member of MAGUK proteins 
family, interaction with the 
cytoskeleton, regulation of 
intracellular junctions
L1CAM Neural cell adhesion 
molecule 1 (NCMA; 
CD56)
Cell- cell adhesion, synaptic 
plasticity
LSP1 Lymphocyte- specific 
protein
F- actin- binding protein in 
endothelia and blood cells
ARHGEF2 Rho- guanine nucleotide 
exchange factor 2
Activate GTPases; facilitate 
actin dynamics
ARHGEF7 Rho- guanine nucleotide 
exchange factor 7
ARHGAP35 Rho GTPase- activating 
protein 35
Activates G proteins and their 
GTPase activity
ARHGAP39 Rho GTPase- activating 
protein 39
Activates G proteins and their 
GTPase activity
ARHGAP1 Rho- GTPase activating 
protein 1
Activates G proteins and their 
GTPase activity
PKP4 Plakophilin- 4 Cadherin- binding protein
MARCKS Myristolated alanine- 
rich C- kinase 
substrate
Actin and calmodulin binding
MARCKSL1 MARCKS- related 
protein
When phosphorylated by 
MAPK8, induces actin 
bundles formation and 
stabilization, thereby 
reducing actin plasticity
CPNE6 Colpine- 6 Calcium- dependent 
membrane- binding protein
ANLN Actin- binding protein 
anillin
Actin- binding protein
ABLIM1 Actin- binding LIM 
protein
Actin- binding protein
GMP6A Neuronal membrane 
glycoprotein M6- a
Extracellular matrix assembly; 
organization actin 
cytoskeleton; GMP6A 
expressed in neurons, 
GMP6B expressed in 
neurons and glial cells
GMP6B Neuronal membrane 
glycoprotein M6- b
PNN Pinin Cell adhesion; RNA splicing
SYNPO2 Synaptopodin Actin- binding protein, 
transport
PVRL1 nectin1 Nectin cell adhesion 
molecule 1
Calcium- independent cellular 
adhesion
GAP43 Growth associated 
protein 43
Protein associated with axonal 
cone growth
CRMP1 Collapsin response 
mediator protein 1
The encoded protein is 
thought to be a part of 
the semaphorin signal 
transduction pathway 
implicated in semaphorin- 
induced growth cone 
collapse during neural 
development
TA B L E  3  (Continued)
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I– II FC III– IV
FC 
V– VI
MAG12 Membrane associated 
guanylate kinase
MAGUK protein; localized at 
the junctional complexes 
and synapses
CCDC6 Coiled- coil domain- 
containing protein 6
Protein of the cytoskeleton




containing protein D2; 
multi- pass membrane 
domain
LMNA Prelamin- A7C Stability of the nuclear 
membrane
EPB41L1 Band 4.1- like protein 1 Stabilizes D2 and D3 receptors 
at the plasma membrane
EPB41L2 Band 4.1- like protein 2 Required for dynein- dynactin 
complex
EPB41L3 Band 4.1- like protein 3 Cytoskeletal anchoring at the 
plasma membrane
X
DMD Dystrophin Anchors the extracellular 
matrix to the cytoskeleton 
via F- actin
ABI2 Abl interactor 2 Regulator of actin cytoskeleton 
dynamics underlying cell 
motility and adhesion
CCDC92 Coiled- coil domain- 
containing protein 92
Localized in the cytoskeleton 
and cytoplasm; unknown 
function
SGIP1 SH3GL interacting 
endocytic adaptor 1
Localization: cytoskeleton; 
signaling by receptors in 
neuronal systems involved 
in energy homeostasis 
via its interaction with 
endophilin
DMTN Dematin Membrane- cytoskeleton- 
associated protein with F- 
actin- binding activity that 
induces F- actin bundles 
formation and stabilization
TAGLN2 Transgelin Actin filament binding
SHROOM2 Protein shroom2 Cell junctions
MLLT4 Afadin Zonula adherens
DST Dystonin Integrator of intermediate 
filaments
MAP4 Microtubule associated 
protein 4
Microtubule binding
SORBS1 Sorbin and SH3 domain- 
containing protein
Intermediate filaments; target 
of myb1 like 2 membrane 
trafficking protein
KBTBD11 Kelch repeat and BTB 
domain- containing 
protein 11





Armadillo like helical 
domain containing 4
Integral component of the 
membrane
TA B L E  3  (Continued)
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I– II FC III– IV
FC 
V– VI
ITSN1 Intersectin- 1 Interacts with golgin to couple 
the Golgi apparatus with 
the actin network
GPM6B Neuronal membrane 
glycoprotein M6B
Component of rafts
SYNM Synemin Component of the cytoskeleton
Synapsis and dense core vesicles
SYN1 Synapsin- 1 Bundles actin and enhances 
spectrin binding; enriched 
in pre- synaptic terminals
SYN3 Synapsin- 3 Cytoplasmic surface of the 
synaptic vesicle
STXBP1 Syntaxin- binding protein Regulation of the 
transmembrane attachment 
protein receptor syntaxin; 
neurotransmitter release
RIMS1 Regulating synaptic 
membrane exocytosis 
1
Regulation of synaptic 
vesicle exocytosis and 
neurotransmitter release
RPH3A Rabphilin 3A In the pre- synaptic terminal 
modulates Rab3a- 
dependent synaptic vesicle 
trafficking and calcium- 
triggered neurotransmitter 
release; in the post- synaptic 
compartment, regulates 
NMDA receptor stability
BSN Protein Basson Organization of the pre- 
synaptic cytoskeleton
SV2A Synaptic vesicle 
glycoprotein 2A
Prototypic synaptic membrane 
protein regulating action 
potential- dependent 
neurotransmitters release
SV2B Synaptic vesicle 
glycoprotein 2B




PCLO Protein Piccolo Component of the pre- synaptic 
cytoskeleton
CHGA Chromogranin A Member of the granin 
family of neurosecretory 
proteins; modulation of 
neuroendocrine function




DLGAP1 Disks large- associated 
protein 1
Binds to PSD- 95 and facilitates 
the assembly of the post- 
synaptic density of neurons
SYP Synaptophysin Synaptic vesicle glycoprotein
PPHLN1 Periphilin- 1 Found in the soluble fraction 
of bovine chromaffin 
secretory vesicles (function 
not known in brain)
TA B L E  3  (Continued)
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I– II FC III– IV
FC 
V– VI
ANKS1B Ankyrin repeat and 
sterile alpha motif 
domain- containing 
protein 1B
Regulation of synaptic 
plasticity by receptor 
localization to synapse
SHANK SH3 and multiple 
ankyrin repeat 
domain protein
Major scaffold postsynaptic 
density protein which 
interacts with multiple 
proteins and complexes to 
orchestrate the dendritic 
spine and synapse 
formation
DLG2 Disks large homolog 2 Stabilization of synapses
PSD PH and Sc7 domain- 
containing protein
Post- synaptic
DBN1 Debrin Postsynaptic, cytosol
SPARCL1 Sparc- like protein 1 Calcium binding; synaptic 
membrane adhesion
Myelin
MBP Myelin basic protein Myelin protein
PLP1 Myelin proteolipid 
protein
Major myelin protein of the 
CNS
CNP 2′,3′- cyclic nucleotide 3′ 
phosphodiesterase
4% of total myelin proteins; 
also binds to microtubules
ADAM22 ADAM metallopeptidase 
domain 22
Integrin ligand, involved 
in myelination; lacks 
metaloprotease activity




Catalyze the hydrolysis of ATP 
coupled with exchange of 
sodium and potassium 








ABCA2 ATP binding cassette 
subfamily B member 
2
Transport across intra- and 
extracellular membranes
ATP8A1 Phospholipid transportin 
ATPase IA
ATPase- coupled cation 
transmembrane transporter
SLC6A17 Sodium- dependent 
neutral amino acid 
transporter SLC6A17
Amino acid transport; 
localizes at synaptic 
junctions particularly in 
excitatory glutamatergic 
terminals
RTN1 Reticulon 1 Involved in neuroendocrine 
secretion or in 
membrane trafficking in 
neuroendocrine cells
RTN3 Reticulon 3 Modulate the activity of beta- 
amyloid converting enzyme 
1 (BACE- 1), and the 
production of β- amyloid
TA B L E  3  (Continued)
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I– II FC III– IV
FC 
V– VI
RTN4 Reticulon 4 Localization in the 
endoplasmic reticulum 
(ER); morphogenesis of 
the endoplasmic reticulum; 
proper localization 
of proteins in the ER; 
interaction with BACE1




regulator of growth cone 
collapse




GNAO1 Guanine nucleotide- 
binding protein G(o) 
subunit α
Modulators in various 
transmembrane signaling 
systems
STMN2 Stathmin2 Cytoplasmic transport of 
vesicles; regulator of 
microtubule stability. 
When phosphorylated 
by MAPK8, stabilizes 
microtubules and 
consequently controls 
neurite length in cortical 
neurons




G protein coupled receptor 
signalling pathway; cellular 
response to catecholamine 
stimulus
STMN1 Stathmin1 Regulation of the microtubule 
filament system by 
destabilizing microtubules. 
It prevents assembly and 
promotes disassembly of 
microtubules
ASAP1 ArfGAP with SH3 
domain, ankyrin 






nucleotide- gated ion 
channel 2
Channel of unknown function 
in brain
CACNG3 Voltage- dependent 
calcium channel 
gamma 3 subunit
Regulates the trafficking 
to the somatodendritic 
compartment and gating 
properties of AMPA- 
selective glutamate 
receptors. Promotes 
their targeting to the cell 
membrane and synapses 
and modulates their gating 
properties
TA B L E  3  (Continued)
(Continues)
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dysregulated phosphoproteins occurred at stages III– IV 
in the EC and FC. This finding suggests that the great-
est phosphorylation- related activity (hyper- and hypo- 
phosphorylation) occurs at the middle stages of NFT 
pathology.
To learn about the possible implications of dysregu-
lated phosphoproteins linked to the structure and func-
tion of cell membranes, synapses, cytoskeleton, and 
the pathway of β- amyloid formation, β- amyloid pre-
cursor protein (APP), presenilin1 (PSEN1), presenilin 
2 (PSEN2), β- secretase 1 (BACE1), BACE 2 and apoli-
poprotein E (ApoE4), together with the components of 
the γ- secretase complex aph- 1  homolog A, γ- secretase 
subunit (APH1A), APH1B, nicastrin (NCT/NCSTN), 
and presenilin enhancer γ- secretase subunit (PEN2/
PSENEN), and the modulators neprilysin (NEP/MME) 
and insulin- degrading enzyme (IDE) (44), were all incor-
porated into the interactome (Figure 5). In addition to 
several direct and indirect interactions, close interaction 
among the components of the β- amyloid pathway and 
two membrane proteins located in the membrane of the 
endoplasmic reticulum, RETN3, and RETN4, was noted 
in the different stages and regions (Figure 5).
3.6 | Molecular synaptic derangements in the 
EC and FC across NFT stages
We wanted to evaluate the existence of molecular similari-
ties and differences at the synaptic level in the EC and FC 
across NFT staging. To do this, the SynGO tool was used 
(45) to categorize synaptic locations and synaptic processes 
derived from our anatomo- proteomic datasets. Several 
proteins linked to synapse were abnormally regulated. In 
the EC, stages I– II: 37; stages III– IV: 67, and stages V– VI: 
56. In the FC, stages I– II: 34, stages III– IV: 32, and stages 
V– VI: 32. These were analyzed separately using SynGO ac-







I– II FC III– IV
FC 
V– VI
KCNAB2 Voltage- gated potassium 
channel subunit 
beta- 2
Localization plasma membrane 
and cytoskeleton; 
regulation of potassium ion 
transmembrane transport
SCN2A Sodium channel protein 
type 2 subunit alpha
Mediates the voltage- 
dependent sodium ion 
permeability of excitable 
membranes
PITPNM3 Membrane associated 
phosphatidylinosoitol 
transfer protein 3
Transport of phospholipids to 
the cell membranes
SPTBN2 Spectrin beta chain, non- 
erythrocytic 2
Regulates glutamate 
transporter pathway at the 
cell membrane





SLC4A4 Solute carrier family 
4 member 4
Electrogenic sodium 
bicarbonate cotransporter 1 
in the membrane
SLC14A1 Solute carrier family 14 Urea and water 
transmembrane transport
CADPS Calcium- dependent 
secretion activator
Peripheral membrane protein 
required for Ca2+- 
regulated exocytosis of 
secretory vesicle
HEPACAM Hepatic and glial cell 
adhesion molecule
Protein localized to the 
cytoplasmic side of the 
plasma membrane, involved 
in cytoplasm- matrix 
interactions
SEC31A SEC31 homolog A, 
COPII coat complex 
component
Component of the outer layer 
of the coat protein complex 
II
Note: Dysregulated phosphoproteins are marked with as many ↓ or ↑ as the number of phosphosyte sites, indicating hyper- or hypophosphorylation. Note that 
several proteins may have two or more phosphorylation sites with opposite directions.
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TA B L E  4  Dysregulated phosphorylation of kinases, proteins linked to DNA or protein deacetylation, proteins linked to gene transcription 
and protein synthesis, heat- shock proteins, members of the ubiquitin- proteasome system (UPS), and proteins involved in energy metabolism 
in the entorhinal cortex (EC) and frontal cortex area 8 (FC) at different stages of NFT pathology (stages I– II, III– IV and V– VI of Braak) 














DCLK1 Serine/theronine protein 
kinase DCLK1
Integral component of plasma membrane 
and post- synaptic density; protein 
kinase activity
PRKAR2B cAMP- dependent protein 
kinase type II- beta 
regulatory subunit
Colocalizes with PJA2 (Praja Ring 
Finger Ubiquitin Ligase 2) in the 
cytoplasm and at the cell membrane; 
activation of PKA and regulation of 
GDK3 activity; mediates membrane 
association by binding to anchoring 
proteins, including the MAP2 kinase
BRSK1 Serine/threonine protein 
kinase BRSK1
Localization in the cytoskeleton, and 
synapses; phosphorylates CDC25B, 
CDC25C, MAPT/TAU, RIMS1, 
TUBG1, TUBG2 and WEE1
BRSK2 Serine/theronine protein 
kinase BRSK2
Localization in the cytoskeleton, 
endoplasmic reticulum and 
perinuclear region; phosphorylates 
CDK16, CDC25C, MAPT/TAU, 
PAK1 and WEE1
PACSIN1 Protein kinase C and casein 
kinase substrate in 
neurons protein 1
Decreases microtubule stability and 
inhibits MAPT- induced microtubule 
polymerization; participates in 
cellular transport processes by 
recruiting DNM1, DNM2 and 
DNM3 to membranes; plays a role 
in the reorganization of the actin 
cytoskeleton
SRCIN1 SRC kinase signalling 
inhibitor 1
Negative regulator of non- receptor 
protein tyrosine kinase; regulates 
dendritic spine morphology; involved 
in calcium- dependent exocytosis; 
plays a role in neurotransmitter 
release or synapse maintenance
GSK3A Glycogen synthase kinase 
3 alpha
Constitutively active protein kinase 
that acts as a negative regulator in 
the hormonal control of glucose 
homeostasis, Wnt signaling and 
regulation of transcription factors and 
microtubules
CAMK2A Calcium- calmodulin- 
dependent protein 
kinase type II subunit 
alpha
Localization cytoplasm, synapses; 
involved in synaptic plasticity, 
neurotransmitter release and long- 
term potentiation; phosphorylation 
of Thr- 286 locks the kinase into an 
activated state
CAMK2B Calcium- calmodulin- 
dependent protein 
kinase type II subunit 
beta
Reorganization of the actin cytoskeleton 
during plasticity by binding and 
bundling actin filaments in a kinase- 
independent manner; autophosphor- 
ylation of Thr- 287 which turns the 
kinase in a constitutively active form 
after activation by Ca2+/calmodulin
(Continues)













PAK1 Serine/threonine protein 
kinase PAK1
Role in cytoskeleton dynamics, in cell 
adhesion, migration, proliferation, 
apoptosis, mitosis, and in vesicle- 
mediated transport processes 
Phosphorylates and activates 
MAP2K1, and thereby mediates 
activation of downstream MAP 
kinases
X
AKAP- 12 A- kinase anchoring protein 
12
Regulatory subunit of protein kinase 
A (PKA); PKA phosphorylates and 
deactivates proteins that have the 
motif Arginine- Arginine- X- Serine 
exposed; involved in multiple cellular 
signaling pathways; AKAP- 12 anchors 
PKA at the cplasma membrane and 
mitochondria
AAK1 AP2 associated kinase 1 The protein interacts with and 
phosphorylates a subunit of the AP- 2 
complex, which promotes binding 
of AP- 2 to sorting signals found in 
membrane- bound receptors and 
subsequent receptor endocytosis
CAMK4 Calcium- calmodulin- 
dependent protein 
kinase type IV
Regulates the activity of several 
transcription activators, such 
as CREB1, MEF2D, JUN and 
RORA; can activate the MAP 
kinases MAPK1/ERK2, MAPK8/
JNK1 and MAPK14/p38 and 
stimulate transcription through the 
phosphorylation of ELK1 and ATF2; 
mainly involved in intracellular signal 
transduction
MAST1 Microtubule- associated 
serine/threonine- protein 
kinase
Links the dystrophin/utrophin network 
with microtubule filaments via the 
syntrophins; cyoskeletal organization; 
intracellular signal transduction
PRKCG Protein kinase C gamma 
type
Regulation of the neuronal receptors 
GRIA4/GLUR4 and GRIN1/
NMDAR1; modulation of receptors 
and neuronal functions related 
to sensitivity to opiates, pain and 
alcohol; mediation of synaptic 
function; chemical synaptic 
transmission; intracellular signal 
transduction
PRKCE Protein kinase C epsilon 
type
Regulation of multiple cellular processes 
linked to cytoskeletal proteins, such 
as cell adhesion, motility, migration 
and cell cycle, functions in neuron 
growth and ion channel regulation; 
phosphorylates MARCKS
PRKAB2 5′- AMP- activated protein 
kinase subunit beta- 2
Non- catalytic subunit of AMP- activated 
protein kinase (AMPK). In response 
to reduction of intracellular ATP 
levels, AMPK activates energy- 
producing pathways and inhibits 
energy- consuming processes: inhibits 
protein, carbohydrate and lipid 
biosynthesis
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PRKRA Interferon- inducible 
double- stranded RNA- 
dependent protein 
kinase activator Ai
Activates EIF2AK2/PKR in the absence 
of double- stranded RNA (dsRNA), 
leading to phosphorylation of 
EIF2S1/EFI2- alpha and inhibition of 
translation and induction of apoptosis. 
Required for siRNA production by 
DICER1 and for subsequent siRNA- 
mediated post- transcriptional gene 
silencing
WNK1 Serine/threonine- protein 
kinase WKN1
Dynamic behavior of the intermediate 
filament cytoskeleton by 
phosphorylation of vimentin; 
localized in the perinuclear region
CAMK2D Calcium- calmodulin- 
dependent protein 




protein kinase activity, ion channel 
binding, protein homodimerization 
activity, titin binding, protein serine/
threonine kinase activity, sodium 
channel inhibitor activity, titin 
binding; main function in heart and 
skeletal muscle
STK32C Serine/threonine protein 
kinase 32C
Intracellular signal transduction
NUAK1 NUAK family SNF1- like 
kinase 1
Intracellular signal transduction; protein 
phosphorylation; regulation of 
senescence
MINK1 Misshapen kinase 2 Negative regulator of Ras- related Rap2- 
mediated signal transduction to 
control neuronal structure and AMPA 
receptor trafficking
MAGI2 Membrane- associated 
guanyl kinase, WW and 
PDZ domain
Alpha- actinin binding; cell surface 
receptor signalling pathway
Proteins linked to DNA or protein deacetylation
TERF2IP Telomeric repeat- binding 
factor 2- interacting 
protein
Acts both as a regulator of telomere 
function and as transcription 
regulator
HDAC2 Histone deacetylase 2 Deacetylation of lysine residues on the 
N- terminal part of the core histones 
(H2A, H2B, H3 and H4); histone 
deacetylation gives a tag for epigenetic 
repression
SUDS3 Sin3 histone deacetylase 
corepresor complex 
component SD53
Regulatory protein which represses 
transcription and augments histone 
deacetylase activity of HDAC1
SIRT2 NAD- dependent protein 
deacetylase sirtuin 2
NAD- dependent protein deacetylase, 
which deacetylates internal lysines 
on histone and alpha- tubulin as well 
as many other proteins such as key 
transcription factors
FGF12 Fibroblast growth factor 12 Growth factor; lacks N- terminal sequence 
of most FGF member; nuclear 
localization
TP53BP1 Tumor suppressor 
53- binding protein 1
DNA repair
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Proteins linked to gene transcription and protein synthesis
RPLP1 60S acidic ribosomal 
protein P1
Structural component of the large 
ribosomal subunit
RPLP0 60S acidic ribosomal 
protein P0
Component of the large ribosomal 
subunit rRNA binding
CTIF CBP80/20- dependent 
translation initiation 
factor
mRNA translation mediated by the 
cap- binding complex, that takes place 
during or right after mRNA export via 
the nuclear pore complex
RNPS1 RNA binding protein with 
serine rich domain 1
Nucleocytoplasmic shuttling protein of 
mRNAs
PML PML nuclear body scaffold Member of the Trim family. localizes to 






C6orf203 is an RNA- binding protein 
involved in mitochondrial protein 
synthesis
EIF3J Eukaryotic translation 
initiation factor 3J
EIF3J is one of thirteen subunits of 
eukaryotic translation initiation 
factor 3, the largest complex of the 
translation initiation factors
EIF5 Eukaryotic translation 
initiation factor 5
Catalyzes the hydrolysis of GTP bound to 
the 40S ribosomal initiation complex 
with the subsequent joining of a 60S 
ribosomal subunit
EIF4B Eukaryotic translation 
initiation factor 4 beta
eIF4B phosphorylation at Ser504 links 
synaptic activity with protein 
translation
EEF1B2 Elongation factor 1 beta Guanyl- nucleotide exchange activity; 
translation elongation factor activity
SRRM1 Serine/arginine repetitive 
matrix protein 1
RNA splicing factor
SRRM2 Serine/arginine repetitive 
matrix protein 2
RNA splicing factor
SRSF6 Serine/arginine- rich 
splicing factor 6
Plays a role in the alternative splicing of 
MAPT/Tau exon 10
SRSF10 Serine/arginine- rich 
splicing factor 10
In its dephosphorylated form acts as 
a general repressor of pre- mRNA 
splicing
MATR3 Matrin- 3 Internal nuclear framework
SMARCA5 SWI/SNF- related matrix 
associated actin 
dependent regulator of 
chromatin subfamily A 
member 5
Regulator of gene transcription 
modulating chromatin around selected 
genes
GATAD2B Transcriptional repressor 
p66- beta
Transcriptional repressor
MFAP1 Microfibrillar associated 
protein 1
Component of the spliceosome B complex
SLU7 Pre- mRNA- splicing factor 
SLU7
Component of the spliceosome
HNRNPUL2 Heterogeneous nuclear 
ribonucleoprotein U- 
like protein 2
RNA binding; localization in the nucleus
TA B L E  4  (Continued)
(Continues)













YAP1 Transcriptional coactivator 
YAP1
Transcription regulator
GNL1 G protein nucleolar 1 GTPase essential for ribosomal 
pre- rRNA processing and cell 
proliferation
NUCKS1 Nuclear ubiquitous casein 
and cyclin dependent 
kinase substrate 1
DNA- binding transcription activator 
activity, RNA polymerase II- specific
PURB Transcriptional activator 
protein Pur- beta
Binds repeated elements in single- 
stranded DNA
BCLAF1 BCl- 2 associated 
transcription factor
DNA and RNA binding; regulator of 
apoptosis
ATRX Transcriptional regulator 
ATRX
Chromatin remodeling
POLE4 DNA polymerase epsilon 
subunit 4
DNA replication initiation; telomere 
maintenance
HRNPH2 Heterogeneous nucler 
ribonucleoprotein H2
Regulation of RNA splicing
HRNPC Heterogeneous nuclear 
ribonucleoproteins C1/
C2
Binds pre- mRNA and nucleates the 
assembly of 40S hnRNP particles
ACIN1 Apoptotic chromatin 




HSP90AB1 Heat- shock protein 
HSP- 90- beta
Assist the conformational folding or 
unfolding and the assembly or 
disassembly of proteinsHSPA12A Heat- shock protein 70 kDa 
12A
DNAJA4 DnaJ heat- shock protein 
family (Hsp40) member 
A4
HSPB1 Heat- shock protein beta- 1
CDC37 Hsp90 co- chaperone Cdc37
HSPA4L Heat- shock protein 70 kDa 
protein 4L
HSP90AA1 Heat- shock protein HSP 
90alpha
Members of the ubiquitin proteasome system
UCHL1 Ubiquitin- carboxyl- 
terminal hydrolase 
isozyme 1
Ubiquitin- protein hydrolase involved 
both in the processing of ubiquitin 
precursors and of ubiquitinated 
proteins
UBR4 E3 ubiquitin protein ligase 
UBR4
Recognizes and binds to proteins bearing 
specific N- terminal residues for their 
subsequent degradation
USP24 Ubiquitin carboxyl- 
terminal hydrolase 24
Thiol- dependent ubiquitin- specific 
protease activity
UB2O E2/E3 hybrid ubiquitin- 
protein ligase UBE20
E2/E3 hybrid ubiquitin- protein 
ligase that displays both E2 and 
E3 ligase activities and mediates 
monoubiquitination of target proteins
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(CC). Lists may be seen in Table S6. Synaptic interactomes 
showed that the synaptic homeostasis was disrupted the 
most in the EC at the III– IV stage (Figure 6). Several di-
rect and indirect interactions among the components of 
the β- amyloid pathway and altered synaptic proteins were 
noted in the different stages and regions when components 














TRIM2 Tripartite motif containing 
2
Ubiquitin- conjugating enzyme E2 D1- 
dependent E3 ubiquitin- protein ligase
PSMA5 Proteasome subunit alpha 
type- 5
Component of the proteasome, a 
multicatalytic proteinase complex
UFD1L Ubiquitin fusion 
degradationprotein 
1 homolog
Polyubiquitin modification- dependent 
protein binding
Energy metabolism
TALDO1 transaldolase Pentose phosphate pathway
PGM2L1 Glucose 1,6- bisphosphate 
synthase
Catalyzes the transfer of a phosphate 
to glucose- 1- phosphate yielding to 
glucose- 1– 6- bisphosphate
GAPDH Glyceraldehyde 3 phosphate 
dehydrogenase
Catalyzes the sixth step of glycolysis
ATP5B ATP stynthase 1 beta 
mitochondrial
Mitochondrial membrane ATP synthase 
(complex V), production of ATP
PGM1 Phosphoglucomutase- 1 Phosphohexose mutase
PGM3 Phosphoacetylglucosamine 
mutase
Involved in step 2 of the subpathway 
that synthesizes N- acetyl- alpha- D- 
glucosamine 1- phosphate from alpha- 
D- glucosamine 6- phosphate
MDH1 Malate dehydrogenase Mitochondrial enzyme, oxidation of 
malate to oxaloacetate, participation 
in the citric acid cycle
MTFR1L Mitochondrial fission 
regulator 1- like
Regulate mitochondrial organization and 
fission
MDAH1 Malate dehydrogenase 
cytoplasmic
Assisting the malate- aspartate 
shuttle from the cytoplasm to the 
mitochondria
PGK1 Phosphoglycerate kinase 1 First ATP- generating step of the 
glycolytic pathway
BCKDHA 2- oxoisovalerate 
dehydrogenase subunit 
alpha, mitochondrial
Conversion of alpha- keto acids to 
acyl- CoA and CO2; localization 
mitochondrial matrix
ALDOC Fructose- bisphosphate 
aldolase C
Involved in the step 4 of the pathway 
that synthesizes D- glyceraldehyde 
3- phosphate and glycerone phosphate 
from D- glucose
PKM Piruvate kinase Last step of glycolysis; transfer 
of a phosphate group from 
phosphoenolpyruvate to adenosine 
diphosphate yielding one molecule of 
pyruvate and one ATP
TPI1 Triosephosphate isomerase Glycolytic enzyme that catalyses 
the reversible interconversion of 
glyceraldehyde 3- phosphate and 
dihydroxyacetone phosphate
Note: Dysregulated phosphoproteins are marked with as many ↓ or ↑ as the number of phosphosyte sites, indicating hyper- or hypophosphorylation. Note that 
several proteins may have two or more phosphorylation sites with opposite directions.
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3.7 | Immunohistochemistry and 
double- labeling immunofluorescence and 
confocal microscopy
A few antibodies directed against the identified proteins 
in the present study were commercially available. Some 
of them do not work for immunohistochemistry. A selec-
tion of antibodies was utilized to validate phosphoprot-
eomics. Also, we used other phospho- specific antibodies 
based on the hypothesis that some phosphoproteins were 
not detected in our phosphoproteomics approach 
due to instrument sensitivity and TiO2 phosphopep-
tide enrichment- based selectivity. Antibodies against 
ADD1- P, ADD1/ADD2- P, MAP2- P, and PAK1- P were 
chosen for validation of cytoskeletal components; anti-
bodies against NFL- P, kinases p38- P and SAPK/JNK- P, 
and non- phospho- specific antibodies against NFM and 
NFH were added for study. The selection of the late pro-
teins was based on the fact that the expression of p38- P 
and SAPK/JNK- P was already described in advanced 
stages of sAD (46- 48), and increased expression of neu-
rofilaments was already detected in NFTs (49, 50). An 
antibody against catenin β- P was chosen because other 
members of the catenin family showed altered phospho-
rylation, but antibodies against those phosphorylated 
forms did not work in our hands.
In the EC, catenin β- P and p38- P immunoreactivity 
appeared at the first and middle stages of NFT pathology 
as small granules in the cytoplasm of a subpopulation of 
neurons. This pattern was also found for p38- P in many 
neurons of the EC at stages V– VI of NFT pathology. MA 
cases were not stained with MAP2- P and SAPK/JNK- P 
antibodies. NFTs were stained with MAP2- P and SAPK/
JNK- P from the first stages of NFT pathology onwards; 
positive cells increased in number with stage progres-
sion. In MA and cases with NFT pathology, only rare 
filaments were stained with anti- NFL- P antibodies. 
Besides basal staining, a few NFTs were decorated with 
NFL- P antibodies. Similar staining was found with an-
tibodies directed against non- phosphorylated NFM and 
NFH; a subpopulation of NFTs showed increased NFM 
and NFH immunoreactivity. In MA and cases with 
NFT pathology, the nucleus of neurons was dyed with 
anti- PAK1- P antibodies. PAK1- P immunoreactivity was 
marked in NFTs at stages III– IV and V– VI, but only as 
irregular or granular deposits in a few neurons at stages 
I– II. ADD1- P immunoreactivity was found in the cyto-
plasm of neurons and astrocytes in MA and cases with 
NFT pathology. Increased ADD1- P immunoreactivity 
occurred in astrocytes and a subpopulation of NFTs at 
middle and advanced stages of NFT pathology. A sim-
ilar pattern was observed with anti- ADD1/ADD2- P an-
tibodies. Images of selected immunostained sections in 
the EC are shown in Figure 7.
Regarding the FC, catenin β- P and p38- P immunore-
activity was found as small granules in the cytoplasm of 
very few neurons at the first and middle stages of NFT 
pathology. Catenin β- P also decorated a few NFTs, and 
p38- P was found in medium- size neuronal inclusions 
in a subpopulation of neurons at stages V– VI. A few 
cortical neurons showed MAP2- P and SAPK- JNK- P- 
immunoreactive cytoplasmic deposits, a few of them rem-
iniscent of pre- tangles, at stages I– II and III– IV. NFTs 
were stained with MAP2- P and SAPK/JNK- P antibodies 
at stages V– VI. ADD1- P and ADD1/ADD2- P immuno-
reactivity was increased in the cytoplasm and processes 
of astrocytes, and in the cytoplasm of a subpopulation 
of neurons at middle and advanced stages of the disease. 
As occurred in the EC, a subpopulation of NFTs showed 
increased NFL- P, NFM, and NFH immunoreactivity in 
the cerebral cortex. Images of selected immunostained 
sections in the FC are shown in Figure 8, upper panel.
To elucidate the relationship if any between p38- P 
and catenin β- P- immunoreactive cytoplasmic gran-
ules and phospho- tau deposition in neurons, double- 
labeling immunofluorescence with p38- P or catenin 
β- P, and AT8 antibodies was examined with confocal 
microscopy. Double- labeling immunofluorescence and 
confocal microscopy of p38- P and AT8 in the FC at 
stages III– IV showed p38- P in small granules in neu-
rons with early phospho- tau deposits. Double- labeling 
immunofluorescence and confocal microscopy of 
PAK1- P and AT8 in the EC at stages I– II disclosed 
PAK1- P- immunoreactive small granules in the cyto-
plasm of neurons at different stages of phospho- tau 
deposition, including pre- tangles and tangles (Figure 8, 
lower panel).
4 |  DISCUSSION
Analysis of molecular profiles in the human brain has 
several limitations, mainly related to concomitant 
pathologies and post- mortem delay interval between 
death and tissue processing, as well as the region exam-
ined and stage of the disease; this is further complicated 
by the number of cases analyzed and the robustness of 
the methods employed (31, 51). The present study mini-
mizes these limitations. In this line, it is important to 
stress the lack of comorbidities and concomitant pa-
thologies in the present series (15). We analyzed the 
(phospho)proteomic profiles of two cortical regions, 
the EC and the FC. The MA control group must be not 
considered an age- matched control group but rather a 
baseline control of the scenario occurring in middle- 
aged individuals with no NFT pathology. It can be ar-
gued that phosphorylation changes observed at stages 
I– II in the present series may be related to aging. We 
have considered the hypothesis of AD as a continuum 
of an age- related biological process leading to degen-
eration that embodies NFT pathology, and this will be 
discussed below.
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F I G U R E  5  Interactomes of the dysregulated cytoskeletal, membrane, and synaptic (phospho)proteins in the entorhinal cortex (EC) and 
frontal cortex area 8 (FC) at different stages of NFT pathology (stages I– II, III– IV, and V– VI of Braak). A large number of (phospho)proteins 
are dysregulated at the first stages (I– II) in the EC and FC. Most dysregulation occurs at the middle stages (III– IV) of AD- related pathology. 
Dysregulated proteins were artificially combined with proteins linked to β- amyloid formation (red balls), including β- amyloid precursor 
protein (APP), presenilin1 (PSEN1), presenilin 2 (PSEN2), β- secretase 1 (BACE1), BACE 2, apolipoprotein E (ApoE4), aph- 1 homolog A γ- 
secretase subunit (APH1A), APH1B, nicastrin (NCT/NCSTN), presenilin enhancer γ- secretase subunit (PEN2/PSENEN), neprilysin (NEP/
MME), and insulin- degrading enzyme (IDE). Close interactions between the proteins of the membranes and cytoskeleton, and proteins of the 
β- amyloidogenic pathway, are depicted. The endoplasmic reticulum membrane proteins reticulon 3 (RTN3) and reticulon 4 (RTN4) (arrows) are 
constant elements in all the stages and regions
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F I G U R E  6  Functional interactomes of dysregulated synaptic proteins and phosphoproteins in the EC and FC at different stages of NFT 
pathology (stages I– II, III– IV, and V– VI of Braak). A large number of proteins are dysregulated at the first stages (I– II) in the EC and FC. 
Most dysregulation occurs in the middle stages (III– IV) of AD- related pathology. A small number of proteins are not shown because they do 
not interact with the proteins represented in the diagrams. Dysregulated proteins were artificially combined with proteins linked to β- amyloid 
formation (red balls), including β- amyloid precursor protein (APP), presenilin1 (PSEN1), presenilin 2 (PSEN2), β- secretase 1 (BACE1), BACE 2, 
apolipoprotein E (ApoE4), aph- 1 homolog A γ- secretase subunit (APH1A), APH1B, nicastrin (NCT/NCSTN), presenilin enhancer γ- secretase 
subunit (PEN2/PSENEN), neprilysin (NEP/MME), and insulin- degrading enzyme (IDE)
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F I G U R E  7  Immunohistochemistry of selected phosphorylated proteins in the EC at different stages of NFT pathology (stages I– II, III– IV, 
and V– VI of Braak). Phosphorylated catenin- β and p38- P immunoreactivity appear at the first and middle stages of NFT pathology as small 
granules in the cytoplasm of a subpopulation of neurons. This pattern is also found for p38- P in many neurons of the EC at stages V– VI of 
NFT pathology. MAP2- P, NFL- P, and SAPK/JNK- P immunoreactivity is found in neurons with the morphology of NFTs from the first stages 
onwards; the number of affected neurons increases with disease progression. The number of NFL- P- positive neurons is, by far, smaller than 
the number of neurons with MAP2- P pathology in consecutive sections. PAK1- P immunoreactivity is seen in NFTs at stages III– IV and V– VI, 
but as irregular or granular deposits in EC neurons at staged I– II. ADD1- P immunoreactivity increases in astrocytes and in a subpopulation of 
NFTs at middle and advanced stages of NFT pathology. Paraffin sections, lightly counterstained with hematoxylin, bar = 50 μm
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4.1 | Comparison of previous and 
present phosphoproteomics studies in AD- 
related pathology
In the context of AD, pioneering studies identified a few 
abnormally phosphorylated proteins in the hippocam-
pus and cerebral cortex in small numbers of cases with 
AD compared with controls (23, 24, 25, 27). Along with 
those studies, Rudrabhatla et al. (50) used iTRAQ- based 
phosphoproteomics in FC to identify all three phospho-
rylated neurofilament proteins associated with NFT in 
AD. Dammer et al. used IMAC coupled with LC- MS/
MS to identify 253 phosphopeptides with elevated or 
decreased levels in the FC of eight AD cases compared 
with eight controls (post- mortem delay between 3 and 
11 h) (29). In addition to tau, phosphopeptide levels were 
over- represented by proteins associated with the plasma 
membrane, glycoproteins, cytoskeletal binding, synapse, 
small heat shock proteins (HSP 27 and crystallin- αB), 
kinases, and alternative splicing. Interestingly, kinase 
activation linked to heat shock proteins was considered 
a pathogenic mechanism in AD.
Sathe et al. (30) used TMT along with IMAC to enrich 
phosphopeptides in order to examine the frontal gyrus of 
people with AD and age- matched cognitively normal sub-
jects; 350 proteins were significantly altered in AD: 389 
phosphopeptides increased whereas 115 phosphopeptides 
decreased phosphorylation. The categorization of altered 
proteins was based on a human protein reference data-
base (HPRD) (52). Most of the altered phosphorylated 
proteins were localized in the cytoplasm (37%), followed 
by the nucleus (29%), plasma membrane (20%), and ex-
tracellular (8%) sites. The molecular function of abnor-
mally phosphorylated proteins corresponds to adhesion 
molecules (17%), serine/threonine kinases (12%), trans-
port/cargo proteins (7%), and structural proteins, integral 
membrane proteins, and others (24%), mostly involved in 
cell growth and/or maintenance, cell communication, and 
metabolism. Network biology showed several molecules 
involved in RNA processing and splicing, neurogenesis 
and neural development, and the metabotropic glutamate 
receptor 5 (GRM5) calcium- signaling pathway. The main 
concern with this impressive study is the selection made 
of control samples (n = 6) composed of cases with NFT 
pathology stages II, III, and IV (CERAD: 0– 1), and AD 
cases (n  =  11) including those with Braak stages III– VI 
(CERAD: 3). Therefore, we lack data about the alterations 
at early stages of AD- related pathology and the changes 
occurring with disease progression.
The present findings show widespread dysregulated 
protein phosphorylation with brain aging and NFT pro-
gression to sAD. Such alteration is stage- and region- 
dependent, but several proteins are common to the EC 
and FC, and many are dysregulated in two or more stages 
in a particular region. Consequently, there is a core group 
of dysregulated proteins throughout the progression of 
the biological process of “normal” versus “pathological” 
aging. Up- and down- regulation of different phosphory-
lation sites occur in a particular protein in a given stage. 
Multiple phosphorylation of regulatory proteins is com-
mon in physiological and pathological conditions (53- 56).
Our results in advanced stages of sAD are similar to 
those already reported by others, particularly Dammer 
et al. (29), Sathe et al. (30), and Bai et al. (28). Several 
identified dysregulated phosphoproteins are common 
to all of them. The recognition of altered molecular 
pathways, as expressed in GO terms, is also similar in 
the studies mentioned and in our present observations. 
These commonalities support the robustness of our 
phosphoproteomics approach.
4.2 | Protein phosphorylation is altered at 
early stages of NFT pathology
The novelty of the present study is the analysis of the first 
stages of NFT pathology (stages I– II) when compared with 
MA individuals with no NFT pathology, and the continuity 
and evolution of these modifications with NFT progression.
It may be suggested that changes at the first stages 
of NFT pathology are linked to aging rather than to 
NFT pathology, because MA individuals are younger 
than those with NFT pathology restricted to the ento-
rhinal and transentorhinal cortex (stages I– II). In the 
EC, we identified sixty- five dysregulated proteins at 
stages I– II; in the FC eighty- one phosphoproteins were 
dysregulated at stages I– II when compared with MA. 
Comparative analysis in the EC at different stages re-
vealed 22 phosphoproteins common to the three stages, 
10 phosphoproteins common to stages V– VI and I– 
II, and 10 phosphoproteins common to stages III– IV 
and I– II. In the FC, the comparative analysis between 
different stages revealed 21 phosphoproteins common 
to the three stages, 14 (phospho)proteins common to 
stages V– VI and I– II, and 15 phosphoproteins common 
to stages III– IV and I– II. It is worth noting that the in-
volvement of the EC occurs at the first stages of NFT 
pathology according to Braak and Braak. However, the 
FC is not affected by NFTs until stages V– VI. Moreover, 
cases categorized as stages I– II in the present series did 
not have β- amyloid in the EC while only two of them 
had β- amyloid deposits in the FC. In short, dysregu-
lated protein phosphorylation of selected proteins oc-
curs in parallel to the appearance of NFTs in the EC 
but precedes the appearance of NFTs and SPs in the 
FC. These findings are in line with previous observa-
tions showing altered molecular pathways in the FC at 
early stages of AD- related pathology (14).
Tau is one of the many cytoskeletal proteins with al-
tered phosphorylation at the early stages of aging and sAD. 
Although tau interacts with a large number of proteins 
(57), not all dysregulated phosphoproteins identified in the 
present study are functionally linked with tau, thus suggest-
ing that selected dysregulated phosphorylation does not 
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F I G U R E  8  Upper panel: Immunohistochemistry of selected phosphorylated proteins in the FC at different stages of NFT pathology 
(stages I– II, III– IV, and V– VI of Braak). Phosphorylated catenin- β and p38- P immunoreactivity are found as small granules in the cytoplasm 
of very few neurons at the first and middle stages of NFT pathology. Catenin β- P decorates a few NFTs at stages V– VI, and p38- P is found in 
medium- sized neuronal inclusions in a subpopulation of neurons. A few cortical neurons show MAP2- P and SAPK- JNK- P- immunoreactive 
deposits at stages I– II and III– IV. NFTs are stained with MAP2- P and SAPK/JNK- P antibodies at stages V– VI. ADD1- P immunoreactivity is 
increased in the cytoplasm and processes of astrocytes, and the cytoplasm of a subpopulation of neurons at the middle and advanced stages 
of the disease. Paraffin sections lightly counterstained with hematoxylin, bar = 50 μm. Lower panel: Double- labeling immunofluorescence 
and confocal microscopy of p38- P (green) and AT8 (red) in the FC at stages III– IV, and PAK1- P (green) and AT8 (red) in the EC at stages I– II. 
p38- P is found as small granules in neurons with early phospho- tau deposits; PAK1- P is found as small granules in neurons at different stages 
of phospho- tau deposition including pre- tangles and tangles. Nuclei are labeled with DRAQ5TM (blue). Paraffin sections, bar = 20 μm
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necessarily depend on the abnormal phosphorylation state 
of tau.
Considering the total number of identified dysreg-
ulated phosphoproteins, the most active period corre-
sponds to stages III– IV, at the time when a subpopulation 
of people might be clinically categorized as suffering 
from a mild cognitive impairment which is a preceding 
determinant stage in the progression to dementia.
4.3 | Categorization of dysregulated 
phosphoproteins and implications in 
brain function
The main group of dysregulated phosphoproteins is com-
posed of membrane proteins, proteins of the cytoskele-
ton, proteins of the synapses and dense core vesicles, and 
proteins linked to membrane transport and ion channels, 
accounting for a total of 141 proteins. Thirty- six proteins 
are abnormally phosphorylated in the EC at stage I– II 
while forty- seven proteins are abnormally phosphoryl-
ated in the FC at stage I– II. Proteins categorized as ki-
nases, proteins linked to DNA or protein deacetylation, 
proteins linked to gene transcription and protein synthe-
sis, and proteins involved in energy metabolism form a 
second instrumental group. Nineteen proteins, includ-
ing nine kinases, are abnormally phosphorylated in the 
EC at stages I– II of NFT pathology compared with MA. 
Twenty- five dysregulated phosphoproteins are identified 
in the FC at stages I– II; six are kinases.
Analyzing the functional implications of dysregulated 
protein phosphorylation of such a large number of pro-
teins is not an easy task. Bioinformatics approaches such 
as GO terms of biological function are useful as instru-
ments, but a list of GO terms is often, as in the present 
scenario, overwhelming. Moreover, the functional con-
sequences of altered phosphorylation, particularly those 
involving hyper- and hypophosphorylation in different 
sites of the protein at a given time, are not known. Since 
the functional consequences of altered tau phosphoryla-
tion have been extensively studied, this point will not be 
discussed. For these reasons, only a few of the selected 
groups of proteins such as kinases, proteins of the syn-
apses, and the amyloidogenic pathway are discussed here 
in greater detail. Thus, twenty four kinases are abnor-
mally phosphorylated across NFT staging in the EC and 
FC. However, this is an underrepresentative number, as 
other kinases were not recognized in our (phospho)pro-
teomics study. p38- P and SAPK/JNK- P are expressed 
in selected EC and FC neurons in all the stages of NFT 
pathology. Immunohistochemistry and double- labeling 
immunofluorescence and confocal microscopy reveal 
phosphorylated p38 as small cytoplasmic granules in 
neurons with small deposits of P- tau; only at advanced 
stages is p38- P incorporated in a subpopulation of NFTs. 
SAPK/JNK- P immunoreactivity co- localizes with NFTs 
in the EC at stages I– II, but it is only at stages III– IV 
that phosphorylated SAPK/JNK accompanies small de-
posits of P- tau in the FC. Therefore, early and persistent 
activation of kinases appears to play a crucial role in the 
dysregulated phosphorylation of proteins in brain aging 
and sAD.
Synaptic pathology is a decisive substrate of cognitive 
impairment and dementia in AD (58- 61). Most studies are 
focused on the deleterious effects of soluble toxic forms 
of β- amyloid and tau at the synapses (62- 65). Oxidative 
stress damage, inflammation, and epigenetic and signal 
transduction alterations are involved as well (66- 69). 
Previous studies in four mouse models of AD showed 
a connection between early β- amyloid deposition in the 
brain and phosphorylation of proteins linked to synap-
tic spine formation. Systems biology analyses suggested 
that phosphorylation of myristoylated alanine- rich C 
kinase substrate MARCKS by overactivated kinases in-
cluding protein kinases C and calmodulin- dependent ki-
nases initiated synapse pathology (70). The present study 
identifies MARCKs phosphorylation and activation of 
several different types of CAMKs and PKCs, some of 
them at the first stages of NFT pathology; this occurs 
in parallel to dysregulated phosphorylation of synaptic 
proteins in the FC and EC at different stages of NFT 
pathology, some of it before the appearance of β- amyloid 
deposits in FC and EC.
Phosphorylation of selected membrane proteins also 
has an impact on the amyloidogenic pathway. APP is 
phosphorylated in AD, and its phosphorylation at spe-
cific sites promotes APP processing and facilitates β- 
amyloid production (71- 73). The possibility that changes 
in the phosphorylation of other membrane proteins 
also interfere with the amyloidogenic pathway of APP 
degradation is suggested by analysis of interactomes of 
APP- related proteins and selected membrane proteins. 
Among these, RTN3 and RTN4/NOGO- B interact with 
BACE1 and reduce the production of β- amyloid and 
the amount of β- amyloid plaques (74- 76). According to 
PhosphoSitePlus database, RTN3 and RTN4 have more 
than twenty phosphorylation sites across the amino 
acid sequence. However, little is known about the con-
sequences of RTN3 and RTN4  hypophosphorylation 
and its functional effects on BACE1 and other putative 
interactors, as it occurs in the EC and FC at the middle 
stages of NFT pathology. As a working hypothesis, al-
tered phosphorylation of RTN3 and RTN4 may modu-
late the β- amyloidogenic pathway, thus contributing to 
SP formation.
4.4 | Is there a link between lipid 
microdomains at the cell membrane, 
diacylglycerol, and altered protein 
phosphorylation?
Lipid rafts are microdomains of the plasma membrane, en-
riched in gangliosides, glycosphingolipids, and cholesterol. 
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Lipid rafts facilitate communication between extracellular 
stimuli and the intracellular milieu through ion channels 
and a variety of signaling receptors; moreover, membrane 
proteins and components of the cytoskeleton anchor in 
and bind to lipid rafts and regulate receptor activation, 
signaling pathways, and cellular polarity (77). The lipid 
composition of lipid rafts is altered in aging and more dra-
matically in AD (78- 81). Experimental pieces of evidence 
point to the facilitation of β- amyloid production linked to 
the abnormalities in the lipid raft composition in lipid rafts 
in AD (82- 84). The present observations showing altered 
phosphorylation of proteins linked to the cell membrane, 
membrane signaling, cytoskeleton and synapses, lead to 
thinking about enhancer complementary unfavourable ef-
fects of lipids and proteins at the level of cell membrane/
cytoskeleton signaling in aging and AD.
It is also worth considering as a working hypoth-
esis that dysregulated phosphoproteins, including 
tau and β- amyloid, converge and point to alterations 
in the diacylglycerol- mediated signaling pathway. 
Diacylglycerol (DAG) has unique functions as a constit-
uent of cell membranes, intermediate lipid metabolism, 
and a key component in lipid- mediated signalling (85, 86). 
In neurons, DAG modulates several signal transduction 
proteins (87), which, in turn, are linked to the activation 
of ion channels, protein kinases, traffic and fusion of 
synaptic vesicles, axonal guidance, and cytoskeletal ho-
meostasis, among others (85, 87, 88). Significantly, tau 
and β- amyloid phosphorylation may also be mediated 
by diacylglycerols and protein kinase C (89, 90). Levels 
of glycerophospholipids, sphingolipids, and DAGs are 
altered in the brain in AD (91). Specifically, the most 
unique and consistent finding of these lipidomics studies 
is the increase of DAG levels in the AD frontal cortex 
(92,93). Further studies are needed to learn about the 
function of DAG in protein phosphorylation in AD.
4.5 | Final considerations
The present findings provide a comprehensive recon-
struction of altered protein phosphorylation in the FC 
and EC, which is line with previous observations at ad-
vanced stages of AD, and provides for the first time ro-
bust data on the first and middle stages of NFT pathology 
linked to AD. It must be stressed that phosphoproteom-
ics has limitations regarding the capacity to recognize 
the totality of phosphoproteins in a given sample and 
the thresholds used to consider an abnormally regulated 
phosphoprotein. This may explain why some proteins ap-
pear to be abnormally regulated at stages I– II and V– VI 
but are apparently normal at stages III– IV, at the time 
that the same protein is abnormally hyperphosphoryl-
ated through NFT progression when assessed with im-
munohistochemistry using phospho- specific antibodies.
We do not know to what extent dysregulated protein 
phosphorylation contributes to degeneration in aging 
and sAD, but it may be hypothesized that the impres-
sive involvement of proteins of membranes, synapses, 
and cytoskeleton, together with altered activation of 
several kinases, impairs brain function and contributes 
to abnormal membrane signal transduction, synaptic 
transmission, β- amyloid processing, and axonal and 
membrane transport. The key point of the present work 
is the demonstration that dysregulated protein phos-
phorylation occurs at the first stages of NFT pathology, 
linking brain aging to sAD. Even considering the plastic 
capacity of the nervous system, altered phosphorylation 
of crucial brain proteins foreshadows impaired brain 
function that may underlie cognitive deficits interpreted 
as normal brain aging in individuals at the first and mid-
dle stages of NFT pathology.
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TABLE S3 Annotation of GO terms for dysregulated 
(phospho)proteins in the EC at different stages of NFT 
pathology
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and V– VI of NFT pathology compared with middle- 
aged (MA) individuals
TABLE S5 Annotation of GO terms for dysregulated 
(phospho)proteins in the FC at different stages of NFT 
pathology
TABLE S6 Dysregulated synaptic proteins as revealed 
with SynGO showing the total number of proteins, and 
proteins classified according to the biological process 
(BP) and the cellular component (CC) in the EC and FC 
at different stages of NFT pathology. Duplicates are seen 
in both lists (BP and CC); for example, SNCB has an-
notation BP (synaptic vesicle endocytosis- GO:0048488) 
and CC (presynaptic cytosol- GO:0099523). The same 
protein may appear several times
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